Bergenbio ASA (BGBIO) - Cash Flow Conversion Efficiency

Latest as of December 2024: -1.249x

Based on the latest financial reports, Bergenbio ASA (BGBIO) has a cash flow conversion efficiency ratio of -1.249x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Nkr-153.24 Million ≈ $-16.13 Million USD) by net assets (Nkr122.70 Million ≈ $12.91 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Bergenbio ASA - Cash Flow Conversion Efficiency Trend (2014–2024)

This chart illustrates how Bergenbio ASA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BGBIO current and long-term liabilities for a breakdown of total debt and financial obligations.

Bergenbio ASA Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bergenbio ASA ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
AHT Syngas Technology NV F:3SQ1	0.008x
JW Pharmaceutical Corp KO:001067	0.132x
Nelson Resources Ltd AU:NES	-0.099x
Openlearning Ltd AU:OLL	0.356x
PLENUM AG NA O.N. F:PLEK	N/A
PLAYWITH Inc KQ:023770	0.105x
Discoverie Group PLC LSE:DSCV	0.070x
Encres Dubuit SA PA:ALDUB	0.056x

Annual Cash Flow Conversion Efficiency for Bergenbio ASA (2014–2024)

The table below shows the annual cash flow conversion efficiency of Bergenbio ASA from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see Bergenbio ASA market cap and net worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	Nkr122.70 Million ≈ $12.91 Million	Nkr-153.24 Million ≈ $-16.13 Million	-1.249x	+43.24%
2023-12-31	Nkr127.48 Million ≈ $13.41 Million	Nkr-280.50 Million ≈ $-29.52 Million	-2.200x	+32.44%
2022-12-31	Nkr88.50 Million ≈ $9.31 Million	Nkr-288.23 Million ≈ $-30.33 Million	-3.257x	-312.75%
2021-12-31	Nkr384.43 Million ≈ $40.45 Million	Nkr-303.34 Million ≈ $-31.92 Million	-0.789x	-125.73%
2020-12-31	Nkr670.23 Million ≈ $70.53 Million	Nkr-234.29 Million ≈ $-24.65 Million	-0.350x	+58.28%
2019-12-31	Nkr219.75 Million ≈ $23.12 Million	Nkr-184.15 Million ≈ $-19.38 Million	-0.838x	-51.38%
2018-12-31	Nkr337.28 Million ≈ $35.49 Million	Nkr-186.71 Million ≈ $-19.65 Million	-0.554x	-15.37%
2017-12-31	Nkr350.35 Million ≈ $36.87 Million	Nkr-168.11 Million ≈ $-17.69 Million	-0.480x	+40.84%
2016-12-31	Nkr153.27 Million ≈ $16.13 Million	Nkr-124.31 Million ≈ $-13.08 Million	-0.811x	+16.51%
2015-12-31	Nkr64.75 Million ≈ $6.81 Million	Nkr-62.90 Million ≈ $-6.62 Million	-0.972x	-155.71%
2014-12-31	Nkr141.38 Million ≈ $14.88 Million	Nkr-53.72 Million ≈ $-5.65 Million	-0.380x	--

About Bergenbio ASA

OL:BGBIO Norway Biotechnology

Market Cap

$7.75 Million

Nkr73.62 Million NOK

Market Cap Rank

#27467 Global

#257 in Norway

Share Price

Nkr0.47

Change (1 day)

-5.91%

52-Week Range

Nkr0.47 - Nkr2.00

All Time High

Nkr4414.96